actions: 2 (1) disclose information on the class 2 transaction to the Stock Exchange of Thailand (the “SET”) pursuant to the Acquisition and Disposition Notifications (as detailed below in item A (GSG

the ASEAN CIS will be disclosed and distributed to investors in Thailand within the same period as having the duty to disclose and distribute such information to investors in Home Jurisdiction. Yes No

ordinary shares of Modern Pharma Company Limited is a subsidiary of the Company, the Company, therefore, has a duty to disclose the transaction information of the Company to the Stock Exchange of Thailand

months which considered as disposition of assets category 2 as size of transaction more than 15% but less than 50% by CEN need to prepare and promptly disclose information to The Stock Exchange of Thailand

Kewkacha and (2) Mr. Thana Kewkacha, who had resigned, respectively. The appointment was in effect from August 27, 2019. Consequently, the Company is obliged to disclose the information memorandum in

as two separate line items in the audited financial statements for the years ended 31 December, 2016, 2017 and 2018, but are reclassified to be presented as a combined line item, “ interest income from

Limited Management Discussion and Analysis for the Second Quarter ended 30 June 2017 Page 4/22 improved consumer confidence and income of farm households. These drivers combined to support growth momentum

secondly our China PET plant had a planned turnaround in 2Q17 and together the combined impact in Asia was 45KT on reported pro- duction YoY. EBITDA impact in Asia together with IPA increase was therefore $9

households. These drivers combined to support growth momentum and helped offset the still lingered at a low level of private investment and contracted in public spending. As the momentum from the above

the same period last year, reflecting the concentration of domestic demand. This, combined with structural factors such as the expansion of the global value chain and e-commerce, increased the